Literature DB >> 7533356

Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations.

M Yasuhara1, T Hashida, M Toraguchi, Y Hashimoto, M Kimura, K Inui, R Hori, Y Inomata, K Tanaka, Y Yamaoka.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533356

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  27 in total

1.  Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.

Authors:  Wai Johnn Sam; Lai San Tham; Michael J Holmes; Marion Aw; Seng Hock Quak; Kang Hoe Lee; Seng Gee Lim; Krishnan Prabhakaran; Sui Yung Chan; Paul C Ho
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.

Authors:  Sherwin K B Sy; Jules Heuberger; Sireen Shilbayeh; Daniela J Conrado; Hartmut Derendorf
Journal:  AAPS J       Date:  2013-08-30       Impact factor: 4.009

3.  Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.

Authors:  Carlos Orlando Jacobo-Cabral; Pilar García-Roca; Elba Margarita Romero-Tejeda; Herlinda Reyes; Mara Medeiros; Gilberto Castañeda-Hernández; Iñaki F Trocóniz
Journal:  Br J Clin Pharmacol       Date:  2015-06-22       Impact factor: 4.335

4.  Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance.

Authors:  Marie Antignac; Jean Sebastien Hulot; Emmanuel Boleslawski; Laurent Hannoun; Yvan Touitou; Robert Farinotti; Philippe Lechat; Saïk Urien
Journal:  Eur J Clin Pharmacol       Date:  2005-07-01       Impact factor: 2.953

5.  Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy.

Authors:  M J García Sánchez; C Manzanares; D Santos-Buelga; A Blázquez; J Manzanares; P Urruzuno; E Medina
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 6.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 7.  A risk-benefit assessment of tacrolimus in transplantation.

Authors:  M Winkler; U Christians
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

8.  Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation.

Authors:  V Guy-Viterbo; A Scohy; R K Verbeeck; R Reding; P Wallemacq; Flora Tshinanu Musuamba
Journal:  Eur J Clin Pharmacol       Date:  2013-04-16       Impact factor: 2.953

9.  Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats.

Authors:  Y Hashimoto; H Sasa; M Shimomura; K Inui
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

Review 10.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.